0001193125-12-327134.txt : 20120801 0001193125-12-327134.hdr.sgml : 20120801 20120801074925 ACCESSION NUMBER: 0001193125-12-327134 CONFORMED SUBMISSION TYPE: SC TO-T/A PUBLIC DOCUMENT COUNT: 3 FILED AS OF DATE: 20120801 DATE AS OF CHANGE: 20120801 GROUP MEMBERS: B & R ACQUISITION CO SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: AMYLIN PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000881464 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330266089 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC TO-T/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-42168 FILM NUMBER: 12998415 BUSINESS ADDRESS: STREET 1: 9360 TOWNE CENTRE DR STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 6195522200 MAIL ADDRESS: STREET 1: 9360 TOWNE CENTRE DR STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BRISTOL MYERS SQUIBB CO CENTRAL INDEX KEY: 0000014272 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 220790350 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC TO-T/A BUSINESS ADDRESS: STREET 1: 345 PARK AVE CITY: NEW YORK STATE: NY ZIP: 10154 BUSINESS PHONE: 2125464000 MAIL ADDRESS: STREET 1: 345 PARK AVE CITY: NEW YORK STATE: NY ZIP: 10154 FORMER COMPANY: FORMER CONFORMED NAME: BRISTOL MYERS CO DATE OF NAME CHANGE: 19891012 SC TO-T/A 1 d389345dsctota.htm AMENDMENT NO. 5 TO SCHEDULE TO AMENDMENT NO. 5 TO SCHEDULE TO

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE TO

TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1)

OF THE SECURITIES EXCHANGE ACT OF 1934

AMENDMENT NO. 5

 

 

 

AMYLIN PHARMACEUTICALS, INC.

(Name of Subject Company (Issuer))

 

B&R ACQUISITION COMPANY

(Offeror)

BRISTOL-MYERS SQUIBB COMPANY

(Offeror)

 

 

 

COMMON STOCK, PAR VALUE $0.001 PER SHARE

(Title of Class of Securities)

 

032346108

(CUSIP Number of Class of Securities)

 

Sandra Leung, Esq.

General Counsel & Corporate Secretary

P. Joseph Campisi, Jr., Esq.

Vice President & Associate General Counsel

Bristol-Myers Squibb Company

345 Park Avenue

New York, New York 10154

(212) 546-4000

(Name, address, and telephone numbers of person authorized to receive notices and communications on behalf of filing persons)

 

 

Copies to:

David Fox, Esq.

Daniel Wolf, Esq.

Kirkland & Ellis LLP

601 Lexington Avenue

New York, NY 10022

(212) 446-4800

CALCULATION OF FILING FEE

 

 

Transaction Valuation(1)   Amount of Filing Fee(2)
$5,309,403,868.82   $608,457.68

 

 

(1) Calculated solely for purposes of determining the filing fee. The calculation assumes the purchase of 163,768,702 shares of voting common stock, par value $0.001 per share. The transaction value also includes the aggregate offer price for (i) 1,552,376 shares issuable pursuant to the vesting of restricted stock units and (ii) 5,950,014 shares issuable pursuant to outstanding options with an exercise price less than $31.00 per share, which is calculated by (x) multiplying the number of shares underlying an outstanding option with an exercise price less than $31.00 by an amount equal to $31.00 minus the exercise price for such option and (y) dividing such product by $31.00.
(2) The amount of the filing fee was calculated in accordance with Rule 0-11 of the Securities Exchange Act of 1934, as amended, and Fee Rate Advisory #3 for fiscal year 2012, issued September 29, 2011, by multiplying the transaction value by 0.0001146.

 

x Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing.

 

Amount Previously Paid:   $608,457.68    Filing Party:    Bristol-Myers Squibb Company and B&R Acquisition Company
Form of Registration No.:   Schedule TO    Date Filed:    July 10, 2012

 

¨ Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

 

  x Third-party tender offer subject to Rule 14d-1.
  ¨ Issuer tender offer subject to Rule 13e-4.
  ¨ Going-private transaction subject to Rule 13e-3.
  ¨ Amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer.  ¨

If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:

 

  ¨ Rule 13e-4(i) (Cross-Border Issuer Tender Offer)
  ¨ Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)

 

 

 

This Amendment No. 5 to the Tender Offer Statement on Schedule TO (as may be amended from time to time, the “Schedule TO”) amends and supplements the Schedule TO relating to the tender offer by (i) B&R Acquisition Company, a Delaware corporation (“Purchaser”) and a wholly-owned subsidiary of Bristol-Myers Squibb Company, a Delaware corporation (“Parent”) and (ii) Parent, for all of the outstanding common stock, par value $0.001 per share (the “Shares”), of Amylin Pharmaceuticals, Inc., a Delaware corporation (the “Company”), at a price of $31.00 per share net to the seller in cash without interest and less applicable withholding taxes, if any, upon the terms and conditions set forth in the offer to purchase dated July 10, 2012 (the “Offer to Purchase”), a copy of which is attached as Exhibit (a)(1)(A), and in the related letter of transmittal (the “Letter of Transmittal”), a copy of which is attached as Exhibit (a)(1)(B), which, together with any amendments or supplements, collectively constitute the “Offer.”

All information set forth in the Offer to Purchase is incorporated by reference herein in response to Items 1 through 9 and to Item 11 in this Schedule TO and is supplemented by the information specifically provided in this Schedule TO.

Item 7

(a) Source and Amount of Funds or Other Consideration. Item 7(a) of the Schedule TO is hereby amended and supplemented by amending Section 9 (“Source and Amount of Funds”) of the Offer to Purchase by adding the following paragraphs immediately after the last paragraph of the subsection titled “Senior Notes Offering”:

“On July 31, 2012, Parent completed its previously announced Notes Offering. The Notes were issued pursuant to that certain Indenture, dated as of June 1, 1993 (the “Indenture”), between the Company and The Bank of New York Mellon, as trustee (the “Trustee”), as supplemented and amended by the Sixth Supplemental Indenture, dated as of July 31, 2012, between the Company and the Trustee (the “Supplemental Indenture”). The full text of the Indenture, which was filed as Exhibit 4(a) to Parent’s Registration Statement on Form S-3, filed on April 28, 2008, and the Supplemental Indenture, which was filed as Exhibit 99.1 of Parent’s Current Report on Form 8-K filed with the SEC on July 31, 2012, are each incorporated herein by reference.”

Item 11

(a) Agreements, Regulatory Requirements and Legal Proceedings. Item 11(a) of the Schedule TO is hereby amended and supplemented by adding the following paragraph at the end thereof:

“At 11:59 PM New York City time, on Tuesday July 31, 2012, the waiting period applicable to the Offer and the merger under the HSR Act expired. Accordingly, the condition of the Offer relating to the expiration or termination of the HSR Act waiting period has been satisfied. On August 1, Parent issued a press release announcing the expiration of the HSR Act waiting period, a copy of which is filed as Exhibit (a)(5)(O) hereto.”

Item 12

Item 12 of the Schedule TO is amended and supplemented by adding the following exhibits:

 

Exhibit

No.

     
(a)(5)(O)   Press Release issued by Bristol-Myers Squibb Company, dated August 1, 2012.
(b)(1)   Indenture dated as of June 1, 1993 between Bristol-Myers Squibb Company and The Bank of New York Mellon as trustee (incorporated by reference to Exhibit 4(a) of the Registration Statement on Form S-3, filed by Bristol-Myers Squibb on April 28, 2008).
(b)(2)   Sixth Supplemental Indenture dated as of July 31, 2012 between Bristol-Myers Squibb Company and The Bank of New York Mellon as trustee (incorporated by reference to Exhibit 99.1 of the Current Report on Form 8-K filed by Bristol-Myers Squibb on July 31, 2012).

 

2

SIGNATURE

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

B&R ACQUISITION COMPANY
By  

/s/ Demetrios Kydonieus

Name:   Demetrios Kydonieus
Title:   Vice President
Date: August 1, 2012
BRISTOL-MYERS SQUIBB COMPANY
By  

/s/ Demetrios Kydonieus

Name:   Demetrios Kydonieus
Title:   Vice President, Strategy, Alliances & Transactions
Date: August 1, 2012

 

3

EXHIBIT INDEX

 

Exhibit

No.

    
(a)(1)(A)   Offer to Purchase, dated July 10, 2012.*
(a)(1)(B)   Letter of Transmittal (including Substitute Form W-9).*
(a)(1)(C)   Notice of Guaranteed Delivery.*
(a)(1)(D)   Letter from the Information Agent to Brokers, Dealers, Commercial Banks, Trust Companies and Nominees.*
(a)(1)(E)   Letter to Clients for Use by Brokers, Dealers, Commercial Banks, Trust Companies and Nominees.*
(a)(1)(F)   Instruction Form to be Used with the Letter of Transmittal.*
(a)(1)(G)   Summary Advertisement as published in the Wall Street Journal on July 10, 2012.*
(a)(5)(A)   Joint Press Release of Amylin Pharmaceuticals, Inc. and Bristol-Myers Squibb Company, dated June 29, 2012 (incorporated by reference to Exhibit 99.1 to the Current Report on Form 8-K filed by Bristol-Myers Squibb Company with the Securities and Exchange Commission on July 2, 2012).*
(a)(5)(B)   Press Release issued by Bristol-Myers Squibb Company, dated July 10, 2012.*
(a)(5)(C)   Class Action Complaint dated July 3, 2012 (Maxine Phillips v. Amylin Pharmaceuticals, Inc., et al.).*
(a)(5)(D)   Class Action Complaint dated July 3, 2012 (Douglas Peterson v. Amylin Pharmaceuticals, Inc. et al.).*
(a)(5)(E)   Transcript of Town Hall Meeting with Bristol-Myers Squibb Company and Amylin Ohio LLC, dated July 12, 2012 and slide presentation used during the Town Hall Meeting (incorporated by reference to Exhibit (a)(5)(E) to Amendment No. 1 to the Schedule 14D-9 filed by Amylin Pharmaceuticals, Inc. with the Securities and Exchange Commission on July 17, 2012).*
(a)(5)(F)   Amylin Integration Frequently Asked Questions memorandum distributed to Amylin employees on July 17, 2012 (incorporated by reference to Exhibit (a)(5)(F) to Amendment No. 1 to the Schedule 14D-9 filed by Amylin Pharmaceuticals, Inc. with the Securities and Exchange Commission on July 17, 2012).*
(a)(5)(G)   Class Action Complaint dated July 9, 2012 (Susha Halberstam v. Amylin Pharmaceuticals, Inc.) (incorporated by reference to Exhibit (a)(5)(D) to the Schedule 14D-9 filed by Amylin Pharmaceuticals, Inc. with the Securities and Exchange Commission on July 10, 2011).*
(a)(5)(H)   Stipulated Order of Class Certification and Case Management dated July 10, 2012 (Maxine Phillips v. Amylin Pharmaceuticals, Inc., et al.).*
(a)(5)(I)   Amended Class Action Complaint dated July 12, 2012 (Maxine Phillips v. Amylin Pharmaceuticals, Inc., et al.).*
(a)(5)(J)   Class Action Complaint dated July 10, 2012 (James Warnock v. Amylin Pharmaceuticals, Inc., et al.).*
(a)(5)(K)   Class Action Complaint dated July 20, 2012 (Susha Halberstam v. Amylin Pharmaceuticals, Inc., et al.).*
(a)(5)(L)   Class Action Complaint dated July 20, 2012 (Peter Doucet v. Amylin Pharmaceuticals, Inc., et al.).*
(a)(5)(M)   Press Release issued by Bristol-Myers Squibb Company, dated July 26, 2012.*
(a)(5)(N)   Memorandum of Understanding entered into July 27, 2012 (incorporated by reference to Exhibit (a)(5)(L) to Amendment No. 4 to the Schedule 14D-9 filed by Amylin Pharmaceuticals, Inc. with the Securities and Exchange Commission on July 27, 2012).*
(a)(5)(O)   Press Release issued by Bristol-Myers Squibb Company, dated August 1, 2012.
(b)(1)   Indenture dated as of June 1, 1993 between Bristol-Myers Squibb Company and The Bank of New York Mellon as trustee (incorporated by reference to Exhibit 4(a) of the Registration Statement on Form S-3, filed by Bristol-Myers Squibb on April 28, 2008).
(b)(2)   Sixth Supplemental Indenture dated as of July 31, 2012 between Bristol-Myers Squibb Company and The Bank of New York Mellon as trustee (incorporated by reference to Exhibit 99.1 of the Current Report on Form 8-K filed by Bristol-Myers Squibb on July 31, 2012).

 

4

Exhibit

No.

    
(d)(1)   Agreement and Plan of Merger, dated June 29, 2012, by and among Amylin Pharmaceuticals, Inc., Bristol-Myers Squibb Company, and B&R Acquisition Company (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by Bristol-Myers Squibb Company with the Securities and Exchange Commission on July 3, 2012).*
(d)(2)   Tender and Support Agreement, by and among Amylin Pharmaceuticals, Inc., Bristol-Myers Squibb Company, B&R Acquisition Company and certain stockholders of Amylin Pharmaceuticals, Inc., dated June 29, 2012.*
(g)   None.
(h)   None.

 

* Previously filed.

 

5

EX-99.A.5.O 2 d389345dex99a5o.htm PRESS RELEASE ISSUED BY BRISTOL-MYERS SQUIBB COMPANY, DATED AUGUST 1, 2012 PRESS RELEASE ISSUED BY BRISTOL-MYERS SQUIBB COMPANY, DATED AUGUST 1, 2012

Exhibit 99.(a)(5)(O)

 

LOGO

Bristol-Myers Squibb Announces Expiration of the

Hart-Scott-Rodino Waiting Period for Acquisition of Amylin Pharmaceuticals, Inc.

(NEW YORK, August 1, 2012) – Bristol-Myers Squibb Company (NYSE: BMY) (“Bristol-Myers Squibb”) announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976, as amended (HSR), for its tender offer for Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) (“Amylin”) has expired.

Bristol-Myers Squibb initiated on July 10, 2012, through its wholly-owned subsidiary B&R Acquisition Company, a cash tender offer to purchase all outstanding shares of common stock of Amylin for $31.00 per share.

The expiration of the HSR waiting period satisfies one of the conditions to the tender offer, which will expire at 5:00 PM (New York City time) on Tuesday, August 7, 2012, unless extended in accordance with the merger agreement and the applicable rules and regulations of the SEC. The closing of the tender offer is subject to customary terms and conditions, including there being validly tendered a number of shares that constitutes at least a majority of Amylin’s outstanding shares of common stock determined on a fully-diluted basis.

Georgeson, Inc. is acting as information agent for Bristol-Myers Squibb. Evercore Group L.L.C. and Citigroup Global Markets Inc. are serving as financial advisers to Bristol-Myers Squibb in connection with the acquisition and Kirkland & Ellis LLP is its legal adviser. Credit Suisse Securities (USA) LLC and Goldman, Sachs & Co. are serving as financial advisers to Amylin in connection with the acquisition and Skadden, Arps, Slate, Meagher & Flom LLP is its legal adviser.

Forward Looking Statements

This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995, relating to the acquisition of Amylin by Bristol-Myers Squibb and the discovery, development and commercialization of certain biological compounds. Such forward-looking statements are based on current expectations and involve inherent risks

and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among other risks, there can be no guarantee that the acquisition will be completed, or if it is completed, that it will close within the anticipated time period or that the expected benefits of the acquisition will be realized. The actual dilutive impact on earnings per share in the near- and mid-term may differ from the expected impact described in this release. In addition, the compounds described in this release are subject to all the risks inherent in the drug development process, and there can be no assurance that these compounds will receive regulatory approval or be commercially successful. Forward-looking statements in the press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb’s business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb’s Annual Report on Form 10-K for the year ended December 31, 2011, its Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

This press release is neither an offer to purchase nor a solicitation of an offer to sell securities. Bristol-Myers Squibb and B&R Acquisition Company filed with the SEC a tender offer statement on Schedule TO and mailed an offer to purchase, forms of letter or transmittal and related documents to Amylin stockholders. Investors and Amylin stockholders are strongly advised to read the tender offer statement (including an offer to purchase, letter of transmittal and related tender offer documents) and the related solicitation/recommendation statement on Schedule 14D-9 that was by Amylin with the SEC, because they contain important information.

These documents are available at no charge at the SEC’s website at www.sec.gov. The tender offer statement and the related materials may be obtained for free by directing a request by mail to Georgeson, Inc., 199 Water Street, 26th Floor, New York, NY or by calling toll-free (888) 663-7851. In addition, a copy of the offer to purchase, letter or transmittal and certain other related tender offer documents may also be obtained free of charge from Bristol-Myers Squibb by directing a request to: Public Affairs, Telephone No.: (609) 252-6579; E-Mail: jennifer.mauer@bms.com.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit http://www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.

Contacts

Media: Jennifer Fron Mauer, 609-252-6579, Jennifer.mauer@bms.com

Laura Hortas, 609-252-4587, laura.hortas@bms.com

Investors: Timothy Power, 609-252-7509, timothy.power@bms.com

GRAPHIC 3 g389345img01.jpg GRAPHIC begin 644 g389345img01.jpg M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$" M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`P,#_\``$0@`&0#P`P$1``(1`0,1`?_$`)X```(!!`,!```````` M```````(!@0%!PD"`PH!`0`"`@,!````````````````!00&`0,'`A````<` M`0,#`P,#!`,``````0(#!`4&!P@`$1(A$PDQ(A11%1=A,B-!0B06<9$T$0`! M`P,#`@0$!`0&`@,````!$0(#``0%(1(&,4%182(3<8$R%)$C%0?PH<%"L='A M\5(6MJXT633;I*=B.)-TV1[_>(=6#C5M:S9%CLJS=8! MX4:^KP:OF>J=N]5;E-Q=ML',Q4QCOD[)IYZ@UK2XZ:;RD@&MRSC3M5L^H:A0 M]&A*//1MNT!7/I)JPT-XS)GFC1IJ,@DFX!Y$7/\`_,G? M,Y9X*[C9/A;)L=J8B\EK=Q1I]8U=H\=D)!U745S[#93/6[S%F+][IRX``D`* M53HWZ?'OT2K)C&U\MV&ZSFTJ;99]5XQ1=NM=+E:=*1L>,)8H#/(4":#H67J) MM5I]O$5!ZL+QN+Q\[=2A&[A,_B*293;,O!Q1W'/M8++[;.-#5)!WJ2=H.J>I M-=!1A[OE0Y'[UUD6RX@D^@D(@ZG1JA.O7XUOS9RK619M'S!X5VRD&Z#R/>(& M(JF\:.T2N&KEN8@&*=NNBH4Q#?[NX`/J/7$KETS(9&!LK)0X`$@=5U`^7B*[ MYW`+S8<2OK[$QY@3V<-HZ?VR97.&J=T M&BZ)K\JHF:Y?9XZ__3/:NWW38!(1$&DHNIU\AK6>^,O*7*>6N7M=;QZ8DY"M M*3,S691C.Q+NOV*LVNO.OPK!5K-"/R%=1JW?/HY<@$(H*A?`>X!TO MN,;>-QPO8VO$;WHUQ1"02H^&AJ;#E;)^2^T$D0:&>IKEW*4(3SJ:6"\5>HKU MYC9[1#P;VW3K:M59&6D6C%6PV)V@LY;P<0DNH0[V160;*G*BD!S^"8B/8`'K MS!9WN1A,UHP_DC=(`%1K>I/E6)K^PQ3XF7TI/W$I#"[S.@'PZ5)C'5+V,"IS M"/\`L[E]1[>OU\0`I0'Z]P[C]/TZBG67W)3[<35T['^.U3@4C/;R2#5TY9-"K ME+[XIE*IV[E[E[&%OF,%?8FTL,@\@V]XPO:/%O0+\SVI-BL]:9:_OL8T;+BS M?M<5[]_\*@ZW.+&F7+EKPHGG-JJVSSE45NE+&?KR\?5KY"M&[AP^"I3RHJM9 M-RU*S7`Q!!,3G04*3R,7L+$<3R4?''\H;^;CPY'HI]MWAT"?SI2.88Z;DC>- MD^U=G5BH/<:G4>*IIXUT[1SJQG$^0F)<7IO_`+;9MLW/PISBK&[_W^78#`/?Q`>XB M`E'T'M_3JM>Y`GUZC3\>G;\*LVYW_P`)`'0N;&_P!8T7N#6&O<96JQP9JJ_P`J.RH]P`PAV$GK^H!]?_?7F:.1T,8C M>0\$*?'XT1/=[S]X]':L=:QJM)Q+.;QKFF3Z-8H&<5N2M5NFUDE%THV%C$#. M'#DR"!5'"RA2!XE3(`F4.8H`'3.QLY\I>,Q5@W=?S.#6#S-0K^^AQ=F[*7[M MEC$TEY^:4E&*?)%GVRZ;EV;&R+D+F1MSAYVR8Y:]2SH:S4;]`P$,2Q'>0\R2 M0?$(YDX4XN6[1,MKMO'JL4JW3MR)R55&/F^+GR MS,0QT8EDGV6D(>BKH36NF_?)5DE;TJ^91G.>;SR M+L^2'(EL+K`,V=WJO9>Z,B=T2+LU@.NPC%YTR*8^;!D9T[1`!$Y"]A$+Q:<' MR%Q;P7=_-#8LN0#"V9Q89`>B!#I\4JB7O[B8^&>>WQ]M->NM21,Z$;FQD:%3 MY4V^![55>1&04+;*(:3"I:'!)34.VF6HL)F/_P"2X8OXN;C^ZGX,Q$23-9LY M1\SBFLD8O<>W5;RF.DQN2EQ\Y(N(M"GTKV(/>K/BLNW*8R+(P`&"4Z?\AJA# MA68>YBE[>?D8"A_41$/[O3I7&]OHCHN1M<@\P,`>?<`*/D(]OKY=P[_ M`*=P'K`],2.X]ON\1`![]NWZ>@CU[5KCZ3 MI_G7MKMH]8U_RKYW-Z=A'M^H]O7K+&[05))K67/>X;`@KGW]0^H]Q_IVZPUJ M'5RUL+B$"5Y\]SM_(:S*>]KP33."+4?QZ#QX443MWHH%*AURPBQ5IQFTOK=QBNT>7RL:)GAV M[;]!0,+00`4=H3J%KC62DREYRJZL)UFM?<:&1/)A86[6E!(-7`E3U&OPK6+S M"T33XO347\B]@H1WD5S>;ZG)KPDZ16-H*E_=QM<=.ZE'RR1FY5Q& M0_92>ZF1^@5,&QNM_M_;83)V;I+S9/$YRE[P+=">KM@)!)ZGIN/45R;G;\OB MK@PV;7PRAO\`ZV$S;@/[2\Z@>8Z>-./B4YK[/#J9.J95DIW]$JT3'UFTR'*J M2S&W9VUG&9DVT34B&(9!K?I,R/"^#>O?P/>ML7Q M>V?8K5QA9K[%`D@W4'=KS5:00$3-C+T6O3[EC$I)(CX$5CXARDLQ:K@FW]UN MV('L(@0"=V_IU)*>:_P M?E24[%7M+M_S26Z"R/1XO*[T[^-VM)PMUEJ>VO3&)-_,5Z-[2M?=2<0V<`NL M)1*J*IQ0$!,"*G<0ZNN)OK*S_:\_=6D=R1F%(+W,!210]DYB=G*8`)1N'+< M+C;VX/(KV!ILWXADS(FR)[;E`V=5<3]2E/!-*H?#\[DK6Q_0XKAS96Y?V_=, M8WH94M\G9>N_(HSHY:Q?<6H%'V3"+DSP*R/Y2#TRK,(&-@)>PQ+U MD^!FLBD>.>,Y,%/'W$B%3MEE88CC>0N[-V+C?#-:2.+VW+W1N9K]+AT[*?J" M@CK52OLSF<_B;.\DR,C+JWN?I-NUKE4(2"->FFO:F,;\X.:TOPBL?R:-MGJJ M%4@=8>,T.*RN=U56GOLDB=+99VYCY.\&`+XGI+Y$ZCWWDG:;9-<2I`V[#XA7 MCQCCPY"[C-S;.VNMG.;*R0N.[87-5OTIHB>**.IJS0\JY$..LSD-WNG%X&.C M?&&>C<`2.YZK\.]97X?:;$6T)CF=3^H6EBM-9E! M3959*#A0479QR)#"0SCQ3(!Q\1^[U'7S/"39S$X7'V4T4(M\8PK(]L>N]"/5 MH2O4=14CAW(8,-EVPR>G:H.B:=@>]8&YK9M8^7W)&2WW`8 MF\4S>L.X;9+R5X]QULK,G4;ZTL=-VV^A+4:PU5^3]SC%;Q`L73)1HJ051.=` MY`$1`.GW&Y.,UA&21 M9.VQ^^$%I:X.#_I!-QZ MRNK=$.UTA)5[B0O<_(Z=*@16V3BY?C%9;)\ MF/*&*Q.5;3-GAG/)?BW-=/_P#N M'*7M$3+QSKJ&.Y=,W8U&;0/;W=P25147M1`\L?DG5QS2MSK6C-[;G$#Q%G-@ MO-\ON&0=/J%&W!2MLKS$9_Q[;E-#3FDU=C$NSLGLI)%D622H$7*NX$!0-JN\ M!PJ'*LQ\MMND-^8VL]YVXQ`INDT(:'%4`.[0:@DBBTY'S6;%NOFWCMGVK';C M"TC>>H:O4C1?B=$"U4:5R$^2+(,+XU;[>M[L]UQ33Z:AHV]7W"^/.;R-ZP%M M,T^-?581I/9CF"X MA);$'W$@;(05(W#^[:-`I^"+6O+^Z;2K_GV\XY7:O=-1AGJ5$K5]&YQ[2.;ST`>4&/"OO;%,+D4:-!*4 MZ+U0$"D[@!>N:NDGP7*7WN%@?%>6LY,;#ZBW:50G^X`'KX=:ZFR.#-<5999^ M=DEK=0I(_1H)/EVZ#\#6EJ6Y'&&F235!'2J; M-9/19*=;9GH:A2D.K%ECF96I'K<5%$FJA?\`-X`9,G3H<+:?N"&YV%8,G[S1 M>A0UKFN*O>T]"XA7>9ZA:Y+-FG\&CFP(VRXML;G6C@-Q8\?2O=H!T/\`+2IR M]Y`\_:M-<&9B?Y414TORMQW:M9L%61R2BDI-(L%1RE&\UFNP9XQ**LM@JB`3 M!4UBNY$':BS(B7*1NMW!MM?6L3#N#'OAF#O>LKE[]`@>T'8"G4E-*G>16=R8?$8\D]-J"[;E]4^0R.MMW& M?17YDK:<_I]ADZQ/>XT=MT6<,BX_%`S!FDS,NL@'FX\#G)U$DX[QD7&?;#"_ M99OC,)WENCG`$#Q/554ITJ8WD7)&6F$?W8>8(I8JE MI>M\FH_X:;E;+NSK&F67E_S6KI[U2J-4X%I"#48?:ZO%.H6D_@+54KG]FA2D M[N$5Q.;R46!=03&%A964&,PW)H;B,.9#;6R,,CE.YX[JI3KY5"N+Q^0Y#@'V MSRU\MW*2\1A`0SOHFI_'QJWWK;=PW75N->+Z;HZR-]:1?DW^ M#;(8BXDM.]$/]P!&J]RO2E=UD+K-<@L+&[FUL\T&"1``X;5!'8H:VW\"-\W# M2+9SAP76+6QTJS\4MI3H5-U1"%B:R[M]?LU2&RUL+)%P*32OM[1`J*BW>"T0 M00/Z=R=P'OS#E>"Q^-@Q%_"@9>0"21@*ENH7SZ?[5U#A^=OLC^K6I4NM92R- MQT#E:2-?B.U+Y\#;B,)Q7V6-EA11UN-Y<[Z7:VB_DG/DMSFS**1JTTD;LY,H MYKQVXH',`$%$`\>_8>G?[Q7-UD^08Z2W;NQT5A&V(KM:-H/8:+J`1\*2?M-^ MF8K"Y`71VWTUX\RM^HE243N0==:FSW:]_P"17,?DWQMXZ;-`<TM<][`QC"U""-3N!T6I4^?N;[-9#"\;F9:65A:-D!:QK][W M`J$.@1.WQI&<;YW\_3_`+B,3L#/SW:! MY&A+0$VZ^)(0KK52Q/+^:Y&W9;RW_M3ECRXN@:/H:3W\4_&JK`.9_P`@=FJW MQS[%=MWIL#$"`D*G\#YURRSG1S9K&)<)^8&I[W7;U2>4')&3PK3,A>Y?3JM7 M:)#N[I=Z3%VZC3\(S3M:ZD">FJ/7*$B]7*JF;VRC]##YEX=P^YRF6Q,%@8I8 M;6)\;O?>?66-=M1R@JJ:ZZE$1:RSF'+68_&7WZ@'^]<2MD'L-^EKR%)'1!^" M#QJ?Y%SBY&VKD[C->IV[VS3\+Y$Y[RM?U&YZ%Q^HU!I3Z=Q",B7=>NV-1\#* MHW2/B?%_L+@38YL5W#/9JUMP]Q:V0C<'$M MVJ1X`H>B:5XN>8\J%[`(LDLM?N)!NU.G@A`&O=>U3+OD/,(+?'.BR6ZYNV@$"!A0H M-?BJJ$T`ZE:8[B#RRY3;W<\)P*QZ^Y8<@\IUO;67-R-)0J2DQ2H642C5G7$6 M31.%,:#9Z:ZG(HD8]1%(XH*/"@8RJ(&Z3\HP?'\7#)?18]K;&:%GV[_=>27N M!]2DHX-T*`)TUZTZXEFN1YF[9;S9#?)'(3,SVF!&@A0=%:2A"T_G/*E/DJ\3GCN+P8JY*12RA#T1P"#7P<%:5Z5;.8VSXH&Y>W!,D+=0.X7P\M.E M:M\$NR7(-Y;MF?4B"6F)RRP->B8#1IA#/*M3<,RF4;$:Y32F#^',ZF;/>%&3 MA:1?(M4XPIU$S?E'`1;H]%SD$G&K.'$Q3#VG-*EAW%SY#J\[2@#.P)W'5`$U MYEAWNY'=W&4FC>)&C3<"T(T=$(4D^(T'?KI9\!MU@G-QBN(^>TJSNC4.?OZ6 M6ZE.U(P.\1QV_P`&1W,1DM;%?RHQ>*6U]<&>3<'GN')IX=#5#`_&/Q,J\7D$16:58X1#$-% M6U^ENHZ\V)&17U5\H<\IHEK?JO%7%MMS])=5%5T^,J)T%E$B@5,PAUF?F>7R M`?#,_=&X!I5H3:/[1X-[IKJ2>M9MN#X>Q=]Q$U)57KJOC\?,)5WUOXY^.>SZ M-<=;N2.D-=#OX_Y#!ULL.9YC#L%K8E@A.FTM!!_\@>J]_'O6;WA6$R;ON+P.WC504(3P0:) M_M4)=?%AQ6D*VVC'Y=8'!EKL$1C#/;;L#202-J)J@'@FB4ED_;SB< MKBYTETN[\B<0^7VFS;2W>QC1)M/;<`"@[=A M4ZWX!QG861&9[0A1[B6K\#X]S3(8CQ2R[C];M7O&>)65"P[591N.B+2]FD9A MG-64_B099&,=*!'1CA-L`(%_'3(`($(7M]O2;+9R_P`K"QDVT[`C=$0>']3Y MT\P_'.Y#2G*!L-P_EB8JA*-)KJ7&86K+JJ)',NTAS55 M1Q^S_CL'RIW"'"F3N<"SJ M)7H]4-9G4(]D(]S*Z,@L\EGP$7]PJ3AL10"+(B4KKD'*&VEKC\?B9Y)HK%@> MTE5$CO4[:#T#3HT=$\:K/'^*NN9\C?9:!L,M\]S7`=V#0*FI7JO5=:J(OXO> M-+"CNLS6>[5+YVG`3].KM%F=INKRKT&H60CAM.5FCP_YJ32-CY&,='9#^25V M=)DK/A7'Q9ML9Y;DL MADR`:)\:E=N^.G![76\\K"4]M%-8YKFDSC<$ZH>O66OR;W+Y]W'. MY6E61\'Y*MBAURQ:2"?Y`"NV0\@143,(FZCVG*LU;3NG'L%SI`_5@(W#0.`/ M1WF-:D7G!N+W$(B=)=;0U`DCE3JE95N7#O"[WQC<\09.GJQF#+4J(H[*KP,F MX8/(2&A%FSR-_99PQEY)K)-7;0BA77D*P*`)^_D81!<[.9,Y=^4<[_[3WEQ< M`$4C73P[)Y4[''L3^B18F-I=:QL#6J22@/53WZZ^9K"E*^,#B[5+.%QLS'2= MHFV=)L&=5\^\ZC:]595*DVR.5B+-7JQ'6!X=G'-YR*5,WVQ[8F;P\EC`U7-*@NZ[M4.HI/#P'!%1.PO86EI!TBNY7,IBUHN-QRN>J>R6^*L5&L-^55<=.5E%Q%$YN[A4`$2*& M*.^;]Q>3S&XWQ69%R`'CVF>I.B_ZK4:+]O.)PF`LENP8#H?<=HO?I_@E729^ M*/B5)U7.*Y&Q&CU1_EN@3FM5.^5'4K;#Z#_*=F$YY_0YZPG>N4[#<)(P]S/7 MC=8Y"F,D0"I&,0T,\ZSLDTKI2Q)8O;+=C=@8.C6M"(T>'2I/_P">X'V(F0AY M;'-[@.X[B?$N0E?.FEX^<9\LXPU6=J^70SYL6V6>5O%YL]BF7UGNEZNDR8JD MI:[C9Y1122G9EZ)0`3G$J:10`B9"D].JWE\Q>WQCDG=Z8V;0@T:.P#:M6%PE MEBXY(K=H_,>'(=5(":^/X4O>B_&QQJT#5[+M3)+3\GT._I(%T:4PO5K;DS?2 M_P`DG4:55[OA''KG-NO[PRQ73CTB2N+:%8Z%+VW/UGKB26KE\?MEW:EN34?/'"HNG8G?`9RJ(+@)^LVW,\O M/`VW?()`QV[9(T/#'=MH.@^53+CA>$;(99@86.`#71$M=BXNK46Z-UB6R-9L4W"B2CRQ.UP=.WBON MNE7R1%A/Y$#J3+S#/.A=!(87QEX>=T;2I:00?D@`\M*7NX#Q21XD$MTUVU-) M'#0A#^.JU"E_C;XX46AY/%4>IZ@];\7WUINN$U2*TR6!S`VB::.5'*<4,O)- M8]PO+G44;D!XN5!,CDY1,0IS"$JRYWEI;Z9T\EJ#-&(Y"Z%?2"#KXHFG6HV4 MX)BHU)D*D$+KVUUZ4JOQT_&Y'L\`P=7F!F6D1>H8E:=6>P. M5731XBS93"RUNN=OF(N_5^HU&>FZ\:55K%K(V!5=<5&[Q%51-!(1*H9MRKGU M[)>W#L;-;&.<1J]D.QYVM`3<0O8TJXG^W]FRR@;D;>Z8^/W-'S*T;G$_2/X- M-#2?B:XGYS)TJ6K`;,UUTVBLE7@-HBKR*:@C M^.)5#D,4GB<`33`JIO/L^]CVO-O^8F[\IOJ+4VJ>I+4"+T32G,O[=\;C>'-9 M.2WI^8=-=4T[ZU,H'XT.+]7K^%52O1=_C:WQPMTI>L>C2:-9SHTRR2L@>5=O M6A%79_R2*/551*FL*A"%75*``"ANEKN693V+J.7V=MR&AZ,"N3Q-,F\0Q?W5 MK-;B4>P7$;G$HH[#_:J+AAA5T@-:Y:\GM;S*+S'3>0NJ-(R(KC5U"2DFPQG+ M8QM5,[=S4G!/Y./-/V\J"\L_(DN;Q]U`AP!1,0`Y'GWY+"X[$Q.